Nifedipine sustained-release tablets (Ⅱ)

Nifedipine inhibits the influx of calcium ions into cells by blocking the membrane transport of calcium ions in myocardial and vascular smooth muscle, causing decreased myocardial contractility and vasodilation. Animal experiments have shown that by reducing myocardial contractility and peripheral vascular resistance, myocardial oxygen consumption is reduced; by dilating coronary vessels and developing collateral circulation, oxygen supply to myocardial ischemic sites is increased; by inhibiting the consumption of high-energy phosphate compounds, the ability to resist hypoxia is enhanced.

The main ingredient of this product is nifedipine, and its chemical name is: 2,6-dimethyl-4 (2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid dimethyl ester. Its structural formula is: Molecular formula: C17H18N2O6 Molecular weight: 346.34

This product is a yellow tablet.

Used to treat high blood pressure and angina pectoris.

Oral administration: 1 tablet at a time, 1 to 2 times a day, or as directed by a doctor.

1. The reaction is short-lived and the most common symptoms are swelling of the ankles, feet and calves, which can be relieved by taking diuretics. 2. Occasionally, chest pain, headache, flushing, dizziness, palpitations, and decreased blood pressure may occur. 3. Occasionally, abdominal pain, nausea, loss of appetite, constipation, etc. may occur. 4. Gum hypertrophy may occur.

It is contraindicated in patients allergic to nifedipine.

Precautions for children: Children are prohibited. Precautions for pregnancy and lactation: Pregnant women are prohibited. Clinical research on nursing mothers is not sufficient, and it is best not to breastfeed when taking this product. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference literature.

1. When used with other antihypertensive drugs, it may cause extreme hypotension. 2. When used with beta-blockers, it may lead to low blood pressure, inhibit cardiac function, and increase the chance of heart failure. 3. If beta-blockers are suddenly discontinued and this product is started, angina pectoris may occasionally occur, and the dosage of the former must be gradually reduced. 4. When used with drugs with high protein binding rates such as dicoumarol, digitalis glycosides, phenytoin sodium, quinidine, quinine, warfarin, etc., the free concentrations of these drugs often change. 5. When used with nitrates, the effect of treating angina pectoris is enhanced.

Keep away from light and store in sealed container.

20mg

36 months

Qingdao Huanghai Pharmaceutical Co., Ltd.

• Founded in:

  1982-02-10

• Address:

  No. 17, Keyuanjingsi Road, Laoshan District, Qingdao

• Tax NO.:

  91370200163567984Y

• Registered Funds:

  182.18928 million yuan

• Website:

  Log in to view

• Email:

  Log in to view